Mid-Year Health Budget Overspend: Closing a €42 Million Gap Without a Supplementary Budget
You are finance director of a national health purchasing agency with an annual budget of €600 million. At the end of month seven, the forecast outturn shows a €42 million overspend. Drug costs are €28 million above budget after two new oncology products were added to the reimbursement list, and temporary staffing is €19 million over because of a recruitment freeze that failed. Committed savings of €10 million have not materialised. The treasury has told you there will be no supplementary budget. Five months remain. The minister has publicly promised no reduction in services, and the audit committee meets in three weeks. The agency has €6 million in a contingency reserve and 12% of its budget is discretionary. You have already used €2 million of the reserve for a legal settlement.
1. What options do you have to close the €42 million gap, and how would you rank them?
Read the worked answer
Quantify before choosing. The gap is €42m, not €42m minus the full reserve: only €4m of the €6m reserve remains, and using it all would leave no cushion. The 12% discretionary budget is €72m, but much is contractual, so realistic discretionary savings may be €15–20m without service cuts. I would rank options by (a) speed, (b) recurrent versus one-off, (c) service impact, (d) legal and contractual risk, (e) reversibility. Tier 1: recover the €10m committed savings with named owners; freeze non-critical vacancies and convert temporary staffing to managed contracts; delay non-urgent discretionary spend. Tier 2: renegotiate drug prices and apply managed-entry agreements for the two oncology products; recover overpayments. Tier 3: temporary deferral of low-clinical-risk procedures only if clinically endorsed. I would not rely on one-off asset sales to cover recurrent drug costs, because that creates a cliff next year. The preferred package closes the gap with at least €5m of recurrent savings and a small residual risk.
2. How would you present the position to the audit committee and the minister?
Read the worked answer
Audit committee: present a one-page bridge from budget to forecast, split into price, volume and policy effects. State the gap, the actions with owners and dates, the residual risk and the decisions needed. Distinguish forecast from actual and give a sensitivity range. Disclose the failed recruitment freeze and the committed savings shortfall plainly; the committee will find out anyway. Minister: brief privately first. Explain that 'no reduction in services' can be honoured in the short term only by using the remaining reserve, renegotiating drug prices and slowing discretionary spend, but that this is not sustainable. Offer three options with explicit service consequences and legal risk, not a single fait accompli. Agree a public line that is accurate and does not promise what cannot be delivered. Ask for a decision on the drug managed-entry approach and on temporary staffing. Keep a written record of advice and decisions; this protects the agency and the minister.
3. What controls would you put in place to prevent recurrence?
Read the worked answer
Prevent recurrence, not just close the gap. I would introduce a monthly rolling forecast with a 12-month horizon, owned by budget holders, not just finance. For drugs, require a horizon-scanning group and a business case for each new reimbursement that identifies funding before listing. For staffing, replace crude freezes with vacancy control by role and a managed-service option for hard-to-fill posts. Make savings realism a formal test: no savings counted without an owner, a mechanism and a tracker. Set a contingency policy with a minimum reserve, and report the reserve monthly. Add a mid-year review trigger at 5% variance. Publish a corrective action plan to the audit committee and report progress quarterly. Finally, review the incentive effects: if the agency is rewarded for listing drugs but not funded for them, the overspend will recur.